Legend Days Payables Outstanding vs Price To Sales Ratio Analysis

LEGN Stock

USD 45.93 1.95 4.43%

Legend BiotechCorp financial indicator trend analysis is infinitely more than just investigating Legend BiotechCorp recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Legend BiotechCorp is a good investment. Please check the relationship between Legend BiotechCorp Days Payables Outstanding and its Price To Sales Ratio accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend BiotechCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Legend Stock, please use our How to Invest in Legend BiotechCorp guide.

Days Payables Outstanding vs Price To Sales Ratio

Days Payables Outstanding vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Legend BiotechCorp Days Payables Outstanding account and Price To Sales Ratio. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Legend BiotechCorp's Days Payables Outstanding and Price To Sales Ratio is -0.2. Overlapping area represents the amount of variation of Days Payables Outstanding that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Legend BiotechCorp, assuming nothing else is changed. The correlation between historical values of Legend BiotechCorp's Days Payables Outstanding and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Days Payables Outstanding of Legend BiotechCorp are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Days Payables Outstanding i.e., Legend BiotechCorp's Days Payables Outstanding and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

-0.2

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Days Payables Outstanding

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Legend BiotechCorp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Legend BiotechCorp sales, a figure that is much harder to manipulate than other Legend BiotechCorp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company’s stock price to its revenues, calculated by dividing the company’s market cap by its total sales or revenue over a 12-month period.

Most indicators from Legend BiotechCorp's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Legend BiotechCorp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend BiotechCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Legend Stock, please use our How to Invest in Legend BiotechCorp guide.As of the 3rd of May 2024, Selling General Administrative is likely to grow to about 112.1 M, while Tax Provision is likely to drop about 268.9 K.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	462.8M	575.1M	727.4M	365.7M
Total Revenue	89.8M	117.0M	285.1M	299.4M

Other Operating Expenses Total Revenue

Legend BiotechCorp fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Net Receivables	Long Term Debt Total	Inventory	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other
Total Assets		0.82	0.86	0.88	-0.6	0.91	-0.93	0.78	0.91	0.2	0.93	-0.55	0.78	0.81	0.81	0.89	1.0	0.66	0.98	0.93	0.87	0.96	-0.05	-0.89	0.96	0.77
Other Current Liab	0.82		0.97	0.68	-0.42	0.79	-0.76	0.81	0.75	0.52	0.83	-0.78	0.77	0.58	0.54	0.91	0.82	0.32	0.85	0.86	0.75	0.85	-0.32	-0.65	0.67	0.51
Total Current Liabilities	0.86	0.97		0.72	-0.34	0.81	-0.82	0.76	0.81	0.44	0.88	-0.84	0.89	0.63	0.62	0.98	0.85	0.41	0.88	0.93	0.75	0.91	-0.15	-0.71	0.7	0.55
Total Stockholder Equity	0.88	0.68	0.72		-0.78	0.98	-0.98	0.69	0.98	0.03	0.96	-0.32	0.59	0.97	0.97	0.75	0.88	0.89	0.89	0.77	0.97	0.85	-0.13	-0.98	0.9	0.96
Other Liab	-0.6	-0.42	-0.34	-0.78		-0.76	0.69	-0.71	-0.66	-0.09	-0.64	-0.05	-0.1	-0.82	-0.72	-0.31	-0.61	-0.69	-0.59	-0.37	-0.84	-0.49	0.55	0.68	-0.74	-0.84
Net Tangible Assets	0.91	0.79	0.81	0.98	-0.76		-0.98	0.76	0.97	0.14	0.98	-0.42	0.63	0.92	0.91	0.81	0.92	0.78	0.94	0.83	0.97	0.9	-0.2	-0.96	0.9	0.89
Retained Earnings	-0.93	-0.76	-0.82	-0.98	0.69	-0.98		-0.72	-0.99	-0.04	-0.99	0.47	-0.71	-0.93	-0.95	-0.85	-0.93	-0.83	-0.95	-0.87	-0.96	-0.93	0.07	0.97	-0.9	-0.91
Accounts Payable	0.78	0.81	0.76	0.69	-0.71	0.76	-0.72		0.69	0.52	0.74	-0.63	0.63	0.71	0.56	0.7	0.77	0.42	0.77	0.74	0.81	0.74	-0.62	-0.58	0.76	0.65
Cash	0.91	0.75	0.81	0.98	-0.66	0.97	-0.99	0.69		0.09	0.99	-0.46	0.72	0.94	0.96	0.85	0.9	0.85	0.92	0.85	0.95	0.91	-0.05	-0.97	0.88	0.91
Other Assets	0.2	0.52	0.44	0.03	-0.09	0.14	-0.04	0.52	0.09		0.15	-0.5	0.32	0.04	-0.11	0.32	0.18	-0.22	0.15	0.19	0.15	0.1	-0.61	0.05	0.11	-0.02
Cash And Short Term Investments	0.93	0.83	0.88	0.96	-0.64	0.98	-0.99	0.74	0.99	0.15		-0.55	0.76	0.91	0.92	0.9	0.92	0.78	0.95	0.89	0.95	0.94	-0.09	-0.95	0.87	0.87
Net Receivables	-0.55	-0.78	-0.84	-0.32	-0.05	-0.42	0.47	-0.63	-0.46	-0.5	-0.55		-0.89	-0.28	-0.23	-0.81	-0.53	-0.04	-0.57	-0.77	-0.39	-0.67	0.16	0.29	-0.34	-0.18
Long Term Debt Total	0.78	0.77	0.89	0.59	-0.1	0.63	-0.71	0.63	0.72	0.32	0.76	-0.89		0.55	0.55	0.93	0.75	0.41	0.76	0.92	0.58	0.85	0.09	-0.6	0.62	0.47
Inventory	0.81	0.58	0.63	0.97	-0.82	0.92	-0.93	0.71	0.94	0.04	0.91	-0.28	0.55		0.97	0.67	0.8	0.93	0.8	0.69	0.96	0.77	-0.19	-0.92	0.86	1.0
Other Stockholder Equity	0.81	0.54	0.62	0.97	-0.72	0.91	-0.95	0.56	0.96	-0.11	0.92	-0.23	0.55	0.97		0.69	0.81	0.96	0.81	0.71	0.92	0.79	0.03	-0.97	0.85	0.97
Total Liab	0.89	0.91	0.98	0.75	-0.31	0.81	-0.85	0.7	0.85	0.32	0.9	-0.81	0.93	0.67	0.69		0.87	0.51	0.89	0.96	0.76	0.93	0.01	-0.76	0.74	0.61
Total Current Assets	1.0	0.82	0.85	0.88	-0.61	0.92	-0.93	0.77	0.9	0.18	0.92	-0.53	0.75	0.8	0.81	0.87		0.65	0.99	0.92	0.87	0.95	-0.05	-0.89	0.96	0.76
Intangible Assets	0.66	0.32	0.41	0.89	-0.69	0.78	-0.83	0.42	0.85	-0.22	0.78	-0.04	0.41	0.93	0.96	0.51	0.65		0.64	0.53	0.82	0.62	0.09	-0.88	0.75	0.96
Common Stock	0.98	0.85	0.88	0.89	-0.59	0.94	-0.95	0.77	0.92	0.15	0.95	-0.57	0.76	0.8	0.81	0.89	0.99	0.64		0.95	0.88	0.98	-0.07	-0.9	0.92	0.76
Property Plant Equipment	0.93	0.86	0.93	0.77	-0.37	0.83	-0.87	0.74	0.85	0.19	0.89	-0.77	0.92	0.69	0.71	0.96	0.92	0.53	0.95		0.77	0.98	0.02	-0.79	0.81	0.63
Short Long Term Debt Total	0.87	0.75	0.75	0.97	-0.84	0.97	-0.96	0.81	0.95	0.15	0.95	-0.39	0.58	0.96	0.92	0.76	0.87	0.82	0.88	0.77		0.84	-0.3	-0.91	0.89	0.94
Property Plant And Equipment Net	0.96	0.85	0.91	0.85	-0.49	0.9	-0.93	0.74	0.91	0.1	0.94	-0.67	0.85	0.77	0.79	0.93	0.95	0.62	0.98	0.98	0.84		0.0	-0.87	0.86	0.72
Current Deferred Revenue	-0.05	-0.32	-0.15	-0.13	0.55	-0.2	0.07	-0.62	-0.05	-0.61	-0.09	0.16	0.09	-0.19	0.03	0.01	-0.05	0.09	-0.07	0.02	-0.3	0.0		-0.05	-0.09	-0.17
Net Debt	-0.89	-0.65	-0.71	-0.98	0.68	-0.96	0.97	-0.58	-0.97	0.05	-0.95	0.29	-0.6	-0.92	-0.97	-0.76	-0.89	-0.88	-0.9	-0.79	-0.91	-0.87	-0.05		-0.89	-0.91
Non Current Assets Total	0.96	0.67	0.7	0.9	-0.74	0.9	-0.9	0.76	0.88	0.11	0.87	-0.34	0.62	0.86	0.85	0.74	0.96	0.75	0.92	0.81	0.89	0.86	-0.09	-0.89		0.85
Non Currrent Assets Other	0.77	0.51	0.55	0.96	-0.84	0.89	-0.91	0.65	0.91	-0.02	0.87	-0.18	0.47	1.0	0.97	0.61	0.76	0.96	0.76	0.63	0.94	0.72	-0.17	-0.91	0.85

Click cells to compare fundamentals

Legend BiotechCorp Account Relationship Matchups

Legend BiotechCorp fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	287.7M	721.0M	1.1B	1.3B	1.8B	938.8M
Other Current Liab	70.9M	99.2M	211.4M	260.9M	140.1M	147.9M
Total Current Liabilities	127.8M	161.2M	280.3M	297.8M	216.4M	203.5M
Total Stockholder Equity	(122.9M)	280.3M	471.2M	744.3M	1.3B	1.3B
Other Liab	277.8M	277.7M	244.8M	7.9M	7.1M	6.7M
Net Tangible Assets	(123.4M)	277.4M	466.5M	740.9M	852.0M	894.6M
Retained Earnings	(127.3M)	(430.8M)	(817.0M)	(966.5M)	(1.5B)	(1.4B)
Accounts Payable	9.6M	5.2M	7.0M	32.9M	20.2M	13.6M
Cash	83.4M	455.7M	688.9M	786.0M	1.3B	1.3B
Other Assets	665K	4.2M	7.3M	67.7M	1.0	0.95
Cash And Short Term Investments	158.9M	505.7M	882.4M	1.0B	1.3B	1.4B
Net Receivables	35.8M	85.0M	63.2M	90K	157.1M	164.9M
Inventory	1.2M	1.8M	1.7M	10.4M	19.4M	20.4M
Other Stockholder Equity	3.9M	430.8M	817.0M	744.3M	2.6B	2.8B
Total Liab	410.6M	440.8M	647.2M	586.7M	589.9M	522.0M
Total Current Assets	207.1M	592.9M	948.8M	1.1B	1.5B	770.5M
Intangible Assets	5.1M	7.7M	4.7M	3.4M	155.3M	163.0M
Property Plant Equipment	79.4M	121.1M	152.9M	160.8M	184.9M	100.7M
Short Long Term Debt Total	6.1M	3.4M	123.0M	284.5M	328.7M	345.1M
Property Plant And Equipment Net	75.5M	121.3M	155.1M	161.7M	189.7M	135.0M
Current Deferred Revenue	46.3M	55.3M	60.9M	451K	53.0M	34.2M
Net Debt	(77.3M)	(452.3M)	(566.0M)	(501.5M)	(949.4M)	(901.9M)
Non Current Assets Total	80.6M	128.1M	169.6M	231.8M	350.8M	194.9M
Non Currrent Assets Other	665K	4.0M	5.1M	66.8M	152.4M	160.0M
Common Stock Shares Outstanding	132.0M	118.2M	140.9M	159.0M	176.1M	151.5M
Short Term Investments	75.6M	50M	193.5M	239.6M	31.0M	29.5M
Liabilities And Stockholders Equity	287.7M	721.0M	1.1B	1.3B	1.8B	1.1B
Non Current Liabilities Total	282.8M	279.6M	366.9M	288.9M	373.5M	339.7M
Capital Lease Obligations	6.1M	3.4M	2.5M	23.6M	47.3M	49.7M
Other Current Assets	11.3M	580.7M	1.4M	1.1B	12.2M	11.6M
Net Invested Capital	(122.9M)	280.3M	591.7M	1.0B	1.5B	1.6B
Property Plant And Equipment Gross	74.8M	116.5M	155.1M	161.7M	224.7M	140.2M
Accumulated Other Comprehensive Income	(122.9M)	280.2M	471.2M	744.3M	98.9M	94.0M
Net Working Capital	79.3M	431.7M	668.5M	801.3M	1.3B	1.3B
Short Term Debt	1.0M	1.5M	911K	3.6M	3.2M	1.9M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Legend BiotechCorp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Legend BiotechCorp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Legend Biotechcorp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Legend Biotechcorp Stock:

How To Invest In Legend

Details

Is Legend Stock a good investment?

Details

What is Legend BiotechCorp's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend BiotechCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

To learn how to invest in Legend Stock, please use our How to Invest in Legend BiotechCorp guide.

Note that the Legend BiotechCorp information on this page should be used as a complementary analysis to other Legend BiotechCorp's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Legend Stock analysis

When running Legend BiotechCorp's price analysis, check to measure Legend BiotechCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Legend BiotechCorp is operating at the current time. Most of Legend BiotechCorp's value examination focuses on studying past and present price action to predict the probability of Legend BiotechCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Legend BiotechCorp's price. Additionally, you may evaluate how the addition of Legend BiotechCorp to your portfolios can decrease your overall portfolio volatility.

	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Stocks Directory Find actively traded stocks across global markets
	CEOs Directory Screen CEOs from public companies around the world
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is Legend BiotechCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend BiotechCorp. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend BiotechCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.94)

Revenue Per Share

1.619

Quarterly Revenue Growth

1.876

Return On Assets

(0.17)

Return On Equity

(0.52)

The market value of Legend BiotechCorp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend BiotechCorp's value that differs from its market value or its book value, called intrinsic value, which is Legend BiotechCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend BiotechCorp's market value can be influenced by many factors that don't directly affect Legend BiotechCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Legend BiotechCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend BiotechCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend BiotechCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Legend Days Payables Outstanding vs Price To Sales Ratio Analysis

Days Payables Outstanding vs Price To Sales Ratio

Days Payables Outstanding vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Days Payables Outstanding

Price To Sales Ratio

Legend BiotechCorp fundamental ratios Correlations

Legend BiotechCorp Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Legend BiotechCorp fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Legend Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Currrent Assets Other	+ 1.0	Inventory
Cash And Short Term Investments	+ 0.99	Cash
Common Stock	+ 0.99	Total Current Assets
Common Stock	+ 0.98	Total Assets
Total Liab	+ 0.98	Total Current Liabilities

Cash And Short Term Investments	- 0.99	Retained Earnings
Cash	- 0.99	Retained Earnings
Retained Earnings	- 0.98	Net Tangible Assets
Net Debt	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.98	Total Stockholder Equity
Net Debt	- 0.97	Other Stockholder Equity